PGMN3 logo

Empreendimentos Pague Menos S.A. Stock Price

BOVESPA:PGMN3 Community·R$2.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

PGMN3 Share Price Performance

R$3.50
0.80 (29.63%)
37.5% undervalued intrinsic discount
R$5.60
Fair Value
R$3.50
0.80 (29.63%)
31.4% undervalued intrinsic discount
R$5.10
Fair Value
Price R$3.50
AnalystHighTarget R$5.10
AnalystConsensusTarget R$4.80
AnalystLowTarget R$3.40

PGMN3 Community Narratives

AnalystHighTarget·
Fair Value R$5.6 35.4% undervalued intrinsic discount

Brazil's Aging Demographic Will Ignite Digital Pharmacy Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value R$4.8 24.6% undervalued intrinsic discount

Pharmaceutical Retail And Digital Channels Will Expand Market Reach

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value R$3.4 6.5% overvalued intrinsic discount

Brazil Retail Will Falter Amid Digital Competition

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent PGMN3 News & Updates

Why We're Not Concerned About Empreendimentos Pague Menos S.A.'s (BVMF:PGMN3) Share Price

Aug 01
Why We're Not Concerned About Empreendimentos Pague Menos S.A.'s (BVMF:PGMN3) Share Price

There May Be Underlying Issues With The Quality Of Empreendimentos Pague Menos' (BVMF:PGMN3) Earnings

May 14
There May Be Underlying Issues With The Quality Of Empreendimentos Pague Menos' (BVMF:PGMN3) Earnings

Empreendimentos Pague Menos S.A. Key Details

R$13.7b

Revenue

R$9.3b

Cost of Revenue

R$4.4b

Gross Profit

R$4.3b

Other Expenses

R$59.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.09
Gross Margin
31.86%
Net Profit Margin
0.43%
Debt/Equity Ratio
61.0%

Empreendimentos Pague Menos S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Reasonable growth potential and fair value.

3 Risks
3 Rewards

About PGMN3

Founded
1981
Employees
27242
CEO
Jonas Neto
WebsiteView website
www.paguemenos.com.br

Empreendimentos Pague Menos S.A. engages in the retail sale of medicines, perfumes, personal hygiene and beauty products in Brazil. The company offers medicines and health care products in the areas of pediatrics, oncology, psychiatry, urology, orthopedics, dermatology, contraception, pediatric endocrinology, assisted reproduction, geriatric, gastrointestinal and hepatic, pain, fever, and inflammation, diabetes, and endocrinology. It also provides personal care and beauty products, including deodorant, intimate care, and oral hygiene, as well as foot, hair, face, and hand care products; dermo-cosmetics; and repellent, diaper, cloth, and food products, as well as other accessories for moms and babies. In addition, the company offers clothing and accessories, supplements, first aid, food and drink, utilities, and others; and cereals, fibers, vitamins and minerals, first aid, and herbal medicines and natural products. It sells its products through retail stores and online. Empreendimentos Pague Menos S.A. was incorporated in 1981 and is headquartered in Fortaleza, Brazil.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Brazilian Market Performance

  • 7 Days: -2.6%
  • 3 Months: 0.4%
  • 1 Year: -0.8%
  • Year to Date: 10.0%
Over the last 7 days, the market has dropped 2.0%, driven by pullbacks in every sector, especially the Financials sector. Overall the market has been flat in the last year. Earnings are forecast to grow by 12% annually. Market details ›